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Identification of a ligand for the death-domain-containing
receptor Apo3
Scot A. Marsters*, James P. Sheridan*, Robert M. Pitti*, Jennifer Brush†,
Audrey Goddard† and Avi Ashkenazi*
The tumor necrosis factor (TNF) cytokine family
regulates development and function of the immune
system [1]. TNF is expressed primarily by activated
lymphocytes and macrophages and induces gene
transcription or apoptosis in target cells [2,3]. We have
identified a novel relative of TNF that binds to the
recently discovered, death-domain-containing receptor
called Apo3 [4] (also known as DR3, WSL-1, TRAMP or
LARD [5–9]). The Apo3 ligand (Apo3L) is a 249 amino-
acid, type II transmembrane protein. The extracellular
sequence of Apo3L shows highest identity to that of
TNF. We detected Apo3L mRNA in many human tissues
and mapped its encoding gene to chromosome 17p13,
near the p53 tumor-suppressor gene. Soluble Apo3L
induced apoptosis and nuclear factor kB (NF-kB)
activation in human cell lines. Caspase inhibitors
blocked apoptosis induction by Apo3L, as did a
dominant-negative mutant of the cell death adaptor
protein Fas-associated death domain protein
(FADD/MORT1), which is critical for apoptosis induction
by TNF [3]. Dominant-negative mutants of several
factors that play a key role in NF-kB induction by TNF
[10] inhibited NF-kB activation by Apo3L. Thus, Apo3L
has overlapping signaling functions with TNF, but
displays a much wider tissue distribution.
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Results and discussion
To identify new members of the TNF cytokine family,
we searched an expressed sequence tag (EST) database
for sequences that have similarity to TNF. Using a set of
overlapping ESTs that showed homology to TNF, we iso-
lated a full-length cDNA from human fetal kidney that
encoded an as yet undescribed member of the TNF
family; we subsequently named this protein Apo3L. The
cDNA predicts a 249 amino-acid polypeptide (Figure 1a)
with a calculated molecular weight of 27 kDa. Apo3L has
no apparent signal sequence at the amino terminus, but
contains a hydrophobic region between amino-acid
residues 20 and 46, indicating a type II transmembrane
protein topology. The predicted carboxy-terminal extra-
cellular domain (ECD) shows the highest protein
sequence identity (20–23%) to TNF, CD40 ligand, lym-
photoxin β and Apo2 ligand (Apo2L).
We investigated the chromosomal location of the human
Apo3L gene by radiation hybrid analysis (data not shown).
Apo3L showed physical linkage to Stanford Human
Genome Center marker SHGC-31370 (LOD = 6.8), which
maps to chromosome 17p13. Notably, the p53 tumor-sup-
pressor gene is located in the same chromosomal region
[11]. Apo3L is the first member of the TNF gene family
that maps to chromosome 17.
We analyzed the mRNA expression of Apo3L in compari-
son to TNF by northern blot hybridization (Figure 1b–d).
We identified a 2 kb Apo3L transcript in essentially all the
fetal and adult tissues examined. In contrast, TNF
mRNA, expressed as a 2.2 kb transcript, appeared only in
peripheral blood leukocytes (PBLs) and spleen. Apo3L
and TNF transcripts were also differentially expressed in
several human tumor cell lines.
To investigate the signaling pathways engaged by Apo3L,
we generated a polyhistidine-tagged form of the Apo3L
ECD (amino acids 47–249) in Escherichia coli [12]. Purified
soluble Apo3L induced apoptosis in human MCF-7 breast
carcinoma cells or in HeLa S3 cervical carcinoma cells
within a period of 14 hours (Figure 2a,b); apoptosis was
evident by morphological changes, chromatin condensa-
tion and internucleosomal DNA fragmentation. Apo3L-
induced apoptosis was augmented by the translation
inhibitor cycloheximide (Figure 2c), indicating that the
apoptosis was independent of de novo protein synthesis.
Addition of the peptide-based caspase inhibitors DEVD-
fmk and zVAD-fmk (Figure 2a,b), or transfection with the
virus-derived caspase inhibitors CrmA or p35 (Figure 2d),
blocked induction of apoptosis by Apo3L, indicating a
requirement for caspase activity. In addition, transfection
with a dominant-negative mutant [13] of the death-
domain-containing adaptor FADD/MORT1, which is
required for apoptosis induction by TNF through TNF
receptor 1 (TNFR1) and by CD95 ligand through CD95
[3], prevented apoptosis induction by Apo3L. Hence,
Apo3L activates caspases through FADD or a closely
related protein.
Next, we investigated whether Apo3L activates the tran-
scription factor NF-κB. Apo3L induced a marked increase
in NF-κB-specific DNA-binding activity in human embry-
onic kidney 293 cells, as did TNF (Figure 3a). Similar
results were obtained in MCF-7 and in HeLa S3 cells (data
not shown). Transfection with dominant-negative mutants
of cytoplasmic factors involved in TNF-induced, TNFR1-
mediated activation of NF-κB [10], namely, TRADD
(TNFR-associated death-domain protein) [14,15], RIP
(receptor-interacting protein)  [16,17], TRAF2 (TNFR-
associated factor 2) [18], or NIK (NF-κB-inducing kinase)
[19,20], inhibited NF-κB activation by Apo3L or by TNF
(Figure 3b). Thus, Apo3L seems to use the same cytoplas-
mic elements that TNF employs to signal NF-κB activa-
tion. Transfection of MCF-7 cells with dominant-negative
NIK caused marked sensitization to Apo3L-induced apop-
tosis (data not shown), suggesting that NF-κB activation by
Apo3L counteracts cytotoxicity as is the case for NF-κB
activation by TNF [3,10].
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Figure 1
Primary structure and mRNA expression of
Apo3L. (a) Amino-acid sequence of human
Apo3L (Genbank accession number
AF055872). The predicted transmembrane
region is highlighted in blue, and the putative
glycosylated asparagine is typed in bold face
and underlined. (b–d) Northern blot analysis
of Apo3L and TNF mRNA expression in
human fetal and adult tissues and in human
tumor-derived cell lines. Sm. intest., small
intestine; s. muscle, skeletal muscle. Cell
lines analyzed were HL60 promyelocytic
leukemia, HeLa S3 cervical carcinoma, K562
chronic myelogenous leukemia, MOLT4
lymphoblastic leukemia, Raji Burkitt’s
lymphoma, SW480 colorectal
adenocarcinoma, A549 lung carcinoma and
G361 melanoma.
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Induction of apoptosis by Apo3L. (a) MCF-7 cells were pretreated for
1 h with cycloheximide (CHX; 10 µg/ml), and treated for 14 h with
soluble Apo3L (2 µg/ml) in the absence or presence of zVAD-fmk
(100 nM). The cells were stained with Hoechst 33342 dye and
photographed by phase (left) and by fluorescence (right) microscopy.
Arrowheads indicate some of the apoptotic cells (left) and their
condensed nuclei (right). (b) HeLa S3 cells were pretreated with CHX
as in (a), then treated with Apo3L with or without zVAD-fmk or DEVD-
fmk (100 nM), and subjected to DNA-fragmentation analysis. (c) MCF-
7 cells were pretreated with buffer or CHX, then treated for 14 h with
Apo3L, and scored by microscopy. (d) MCF-7 cells were transfected
with control vector (pRK5), or with vectors encoding the caspase
inhibitor p35 or CrmA, or dominant-negative FADD (FADD-DN). After
16 h, the cells were treated with CHX and Apo3L as in (a).
Because Apo3L engaged signaling pathways that were
shown previously to be activated by overexpression of Apo3
[4–8], we tested whether Apo3L binds to Apo3. We gener-
ated a soluble, FLAG-epitope-tagged protein based on the
ECD of Apo3 (FLAG–Apo3). We then examined the ability
of histidine-tagged Apo3L to associate with FLAG–Apo3 in
a co-immunoprecipitation assay (Figure 4a); for comparison,
we tested histidine-tagged Apo2L [12] and a FLAG-
epitope-tagged ECD of its receptor, death receptor 5 (DR5)
[21]. Apo3L bound to Apo3, but not to DR5, whereas
Apo2L bound to DR5, but not to Apo3, indicating specific
complex formation between Apo3L and Apo3. Apo3L did
not bind to soluble Fc fusion proteins based on the ECDs of
other TNFR family members that regulate cell death,
namely, TNFR1, TNFR2, CD95 or DR4 (data not shown).
Preincubation of ligand with FLAG–Apo3, followed by
immunodepletion of complexes with anti-FLAG antibody
inhibited apoptosis induction by Apo3L, but not by Apo2L
(Figure 4b). In addition, transfection of 293 cells, which are
relatively resistant to Apo3L-induced apoptosis, with low
levels of full-length Apo3 cDNA caused marked sensitiza-
tion to Apo3L, but not to TNF (Figure 4c). Thus, Apo3L
interacts with Apo3.
We have identified a ligand that regulates apoptosis and
NF-κB activation through Apo3, similar to the way that
TNF regulates these cellular responses through TNFR1.
A molecule with the same sequence as Apo3L has recently
been described [22]. Our results do not rule out the poten-
tial existence of other ligand interactions for Apo3 or other
receptor interactions for Apo3L. The Apo3L mRNA is
expressed in a wide variety of tissues, in contrast to TNF,
the expression of which is much more restricted. Con-
versely, the tissue distribution of TNFR1 is broad [1],
whereas Apo3 expression appears restricted mainly to lym-
phocyte-rich tissues such as PBLs and spleen [4–8].
Hence, it will be important to investigate the role of
Apo3L–Apo3 interactions in immune system development
and function, for example by gene ‘knockouts’. Whereas
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Figure 3
Activation of NF-κB by Apo3L. (a) Human 293 cells were treated for
3 h with Apo3L or TNF, and NF-κB activity was determined by
electrophoretic mobility shift assay. (b) Human 293 cells were
transfected with control vector (pRK5), or with expression plasmids
encoding dominant-negative (DN) mutants of TRADD, RIP, TRAF2 or
NIK. After 16 h, the cells were treated with Apo3L or TNF and assayed
for NF-κB activation as in (a).
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Interaction of Apo3L with Apo3. (a) Histidine-tagged soluble Apo3L or
Apo2L (5 µg) was incubated for 1 h with FLAG–Apo3 or FLAG–DR5
(1 µg). The reactions were precipitated (IP) with Sepharose-
conjugated anti-FLAG antibody (left) or nickel (right), resolved by gel
electrophoresis, and ligands were visualized by western blot (WB) with
nickel-conjugated horseradish peroxidase and chemiluminescence.
(b) Apo3L or Apo2L (0.5 µg/ml) was incubated with buffer or with
FLAG–Apo3 ECD (5 µg/ml) for 1 h, and immunoprecipitated with anti-
FLAG–Sepharose. The supernatants were added to MCF-7 cells
together with CHX (10 µg/ml) and apoptosis was scored 14 h later.
Precipitation without FLAG–Apo3 did not deplete Apo3L or Apo2L
activity (data not shown). (c) The 293 cell line was transfected with
control plasmid (pRK5) or with plasmid encoding full-length Apo3
(1.5 µg per 106 cells). After 24 h, the cells were treated for 14 h with
CHX with or without Apo3L or TNF (2 µg/ml) and apoptosis was
scored.
Apo3 mRNA levels increased upon T-cell activation [7,8],
Apo3L levels did not (data not shown). Thus, cellular sen-
sitivity to the cytotoxic action of Apo3L might be regulated
in part at the level of Apo3 expression. Additional regula-
tory mechanisms might involve secretion of a soluble Apo3
ECD through alternative mRNA splicing [4–8], NF-κB
activation, and protection by anti-apoptotic factors such as
FLICE-inhibitory protein [23]. Our results indicate that
Apo3L has overlapping signaling functions with TNF, but
differs from TNF in its sites of production, as well as
perhaps in its targets of action.
Materials and methods
Isolation of the Apo3L cDNA
We searched the LifeSeq EST DNA database (Incyte Pharmaceuticals)
for sequences that show homology to the ECD of TNF family members.
We identified a set of overlapping ESTs related to TNF; PCR primers
based on the region of EST consensus were used to screen a number
of human cDNA libraries, of which human fetal kidney was positive for a
PCR product of the expected size. This library was screened by
hybridization to a 60 bp DNA probe based on the ESTs. One positive
clone (DNA30879) was isolated and sequenced in entirety.
Generation of soluble Apo3L
The DNA sequence encoding the ECD of Apo3L (amino acids 47–249)
was amplified by PCR and cloned into the E. coli expression plasmid
pET-19B (Novagen), using NdeI and XhoI restriction sites. The Apo3L
sequence was inserted in-frame and downstream of an initiating methio-
nine, followed by 10 histidine residues, and an enterokinase cleavage
site present in the vector. The protein was expressed in E. coli,
extracted by microfluidization in the presence of protease inhibitors, and
purified by affinity chromatography on nickel–Sepharose, essentially as
described [12]. Gel analysis showed that the purified protein was
capable of forming homotrimers (data not shown).
Analysis of apoptosis
Apoptosis was assessed morphologically by light microscopy, and by
nuclear staining with Hoechst 33342 dye (10 µg/ml) and fluores-
cence microscopy. For each data point, depicted as mean ± s.e.m.,
live and apoptotic cells were scored in three random fields, each con-
taining 100–200 cells. Internucleosomal DNA fragmentation was ana-
lyzed by extracting DNA from cells and 32P-labelling the 3′ ends with
terminal transferase using an Apoptotic DNA Laddering kit (Trevigen).
Samples were separated by electrophoresis on 1.5% agarose gels as
described [12].
Supplementary material
A figure showing a sequence alignment of Apo3L with related proteins
and additional methodological detail are available with this paper on
the internet.
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Materials and methods 
Genomic mapping
The chromosomal location of the human Apo3L gene was determined
by PCR analysis of a panel of 83 human–mouse cell radiation hybrids
(Research Genetics) with primers based on the coding region of the
Apo3L cDNA. The linkages were assigned using the database of the
Stanford Human Genome Center (http://www-shgc.stanford.edu/
Mapping/rh/search.html). Linkage to p53 (Whitehead Institute marker
WI-9178) and to human chromosome 17p13 was established by using
the NCBI Entrez browser (http://www.ncbi.nlm.nih.gov/htbinpost/
Entrez/query?db=c&form=4&field=ORGN&term=Homo+sapiens).
Analysis of mRNA expression
Expression of Apo3L mRNA in human tissues was examined by north-
ern blot analysis. Human fetal and adult RNA blots and a human cancer
cell line RNA blot (Clontech) were hybridized to a 32P-labeled DNA
probe based on the ECD of Apo3L. The probe was generated by PCR
with the primers: 5′-CGACGACAAGCATATGCGGGCATCGCTGTC-
CGCCCAGGAG-3′ and 5′-CAGCCGGATCCTCGAGTCAGTGAAC-
CTGGAAGAGTCCG-3′.
Analysis of NF-κB activation
Cells were harvested after treatment, nuclear extracts were prepared,
and 1 µg nuclear protein was reacted with a 32P-labeled NF-κB-spe-
cific oligonucleotide probe (5′-ATCAGGGACTTTCCGCTGGGGA-
CTTTCCG-3′). DNA binding was analyzed by electrophoretic mobility
shift assay, as described [4].
Transfections and plasmids
Transient transfections were done by standard lipofection (MCF-7
cells) or calcium phosphate precipitation (293 cells). The expression
Supplementary material
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Alignment of the carboxy-terminal sequence of Apo3L with that of TNF, CD40 ligand (CD40L), lymphotoxin β (LTβ), Apo2L, CD95L and LTα. Residues
conserved in two or more ligands are shaded. Regions that form β strands in the crystal structures of TNF and LTα [1] are marked above with lines.
plasmid encoding baculovirus p35 was a kind gift from V. Dixit (Genen-
tech). Expression plasmids encoding CrmA, and dominant-negative
FADD (FADD 80–205) [13], TRADD (Ala 296–299) [15], RIP (RIP
559–671) [16], TRAF2 (TRAF2 87–501) [18], and NIK (NIK
KK429–430AA) [20] were kind gifts from D. Goeddel (Tularik).
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